EUVIMEDEUVIMED entdecken
Crossref

Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice

Claire E Smith, Avina Rami, Tianyu Li, Nabihah Tayob, Pooja Patel, Harold J Burstein, Sandra McAllister, Rachel Abelman, Rachel A Freedman

Breast Cancer Research and Treatment · 2026

DOI: 10.1007/s10549-026-08112-2 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Breast Cancer Research and Treatment, 2026. Verfasst von Claire E Smith und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Claire_smith@dfci.harvard.edu. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Antineoplastic Agents, Immunological. Die Arbeit nennt 33 Literaturangaben. Gefördert von: Samuel Waxman Cancer Research Foundation with the Mark Foundation for Cancer Research, Bakes for Breast Cancer.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Chemotherapy and pembrolizumab treatment can improve survival in triple-negative breast cancer (TNBC), but data are limited in older adults. We examined treatment patterns, efficacy, and safety for older patients on pembrolizumab for early-stage (eTNBC) and metastatic TNBC (mTNBC).

Methods

Through medical record review, we collected tumor, treatment, and outcome data for patients ≥ 65 years receiving pembrolizumab-containing therapy for TNBC between 2021 and 2024. For all, we examined immune related adverse events (irAEs) and hospitalizations. For eTNBC, we examined percent ideal dose, treatment discontinuation, and factors associated with pathologic complete response (pCR). Among patients with mTNBC, progression-free survival (PFS) and overall survival (OS) were analyzed using Kaplan-Meier methods.

Results

Among 136 included patients, median age was 71 (range 63–91); 85 had eTNBC, of whom 42% received the neoadjuvant KEYNOTE-522 regimen. There were 51 with mTNBC who received a variety of regimens. In eTNBC, mean ideal dose was 82%, 43% had a pCR, 41% were hospitalized, 39% experienced irAEs, and 4% had treatment-related deaths. Patients aged > 70 had more irAEs, and lower % ideal dose. No clinical or treatment variables were associated with pCR. In mTNBC, 43% were hospitalized, 18% were admitted to the ICU, and 41% experienced irAEs. With a median follow-up of 29 months, median PFS was 5.45 months (95% CI, 3.8–7.8), and median OS was 23.1 months (95% CI, 18.6–35.4).

Conclusion

In this cohort of older adults with TNBC receiving pembrolizumab-containing treatment, we observed high rates of serious toxicity, with lower-than-expected pCR rates in eTNBC, and short OS in mTNBC. Clinical trial number Not applicable.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedTriple Negative Breast NeoplasmsAntineoplastic Combined Chemotherapy ProtocolsAntineoplastic Agents, ImmunologicalHumansFemaleAgedAged, 80 and overMiddle AgedPathologic Complete ResponseTreatment Outcome

Stichwörter der Autor:innen

Early stageMetastaticOlder patientsOutcomesPembrolizumabTriple-negative breast cancer

Substanzen

Antibodies, Monoclonal, HumanizedpembrolizumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA. Claire_smith@dfci.harvard.edu.
  • Department of Medicine, Harvard Medical School, Boston, MA, USA. Claire_smith@dfci.harvard.edu.
  • Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Internal Medicine, Brigham and Women's Hospital, Boston, MA, USA.
  • Data Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
  • Medical Oncology, Dana-Farber Cancer Institute, 450 Brookline Avenue, Boston, MA, 02215, USA.

Förderung

  • Samuel Waxman Cancer Research Foundation with the Mark Foundation for Cancer Research
  • Bakes for Breast Cancer

Zitieren

APA

Smith, C. E., Rami, A., Li, T., Tayob, N., Patel, P., Burstein, H. J., McAllister, S., Abelman, R., & Freedman, R. A. (2026). Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-026-08112-2

Vancouver

Smith CE, Rami A, Li T, Tayob N, Patel P, Burstein HJ, et al. Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice. Breast Cancer Research and Treatment. 2026. doi:10.1007/s10549-026-08112-2

BibTeX
@article{Smith2026,
  author = {Smith, Claire E and Rami, Avina and Li, Tianyu and Tayob, Nabihah and Patel, Pooja and Burstein, Harold J and McAllister, Sandra and Abelman, Rachel and Freedman, Rachel A},
  title = {Efficacy and toxicity for pembrolizumab-containing therapy in older adults with triple-negative breast cancer: insights from routine oncology practice},
  journal = {Breast Cancer Research and Treatment},
  year = {2026},
  doi = {10.1007/s10549-026-08112-2}
}
Kostenlos starten →